Liliya Koyfman, MD
Psychiatry · Warwick, RINPI 1508800954
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $88,852 of the $110,305 with a category attached, or 80.6%. 8 manufacturers reported payments, led by Alkermes, Inc. at 58.8% of the total. Reporting peaked in 2019 at $39,762 and has fallen 99.9% since, to $58 in 2025. Among psychiatry clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 118 payments — averaging $934.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$65K
- Johnson & Johnson$22K
- Neurocrine Biosciences, Inc.$12K
- E.r. Squibb & Sons, L.L.C.$10K
- Sunovion Pharmaceuticals Inc.$1K
- AbbVie$82
- plus $37 from 2 others
What the payments were for
- Consulting fees$14,80113%
- Speaking & faculty fees$88,85281%
- Travel & lodging$4,0994%
- Food & beverage$2,5532%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 56 | $64,817 |
| Johnson & Johnson | 26 | $21,772 |
| Neurocrine Biosciences, Inc. | 12 | $12,076 |
| E.r. Squibb & Sons, L.L.C. | 16 | $10,451 |
| Sunovion Pharmaceuticals Inc. | 2 | $1,069 |
| AbbVie(2 entities) | 4 | $82 |
| Indivior Inc. | 1 | $24 |
| Vanda Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$257,320
- ARISTADA INITIO$64,330
- INVEGA SUSTENNA$21,532
- INVEGA TRINZA$20,852
- INGREZZA$11,999
- LATUDA$1,069
How this compares
$110,305 in reported general payments places this provider in the 95th percentile of 209 psychiatry providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 143 | $381,792 |
| AristadaAripiprazole Lauroxil | 32 | $118,315 |
| Abilify MaintenaAripiprazole | 13 | $38,022 |
| LybalviOlanzapine/Samidorphan Malate | 17 | $24,851 |
| Risperidone ErRisperidone Microspheres | 15 | $24,588 |
| Clozapine OdtClozapine | 12 | $20,908 |
| Clozapine | 198 | $18,863 |
| Lurasidone Hcl | 64 | $14,769 |
| Paliperidone ErPaliperidone | 63 | $10,434 |
| DepakoteDivalproex Sodium | 13 | $8,021 |
| Aripiprazole | 113 | $7,590 |
| Divalproex Sodium ErDivalproex Sodium | 90 | $6,778 |
| LatudaLurasidone Hcl | 13 | $6,657 |
| Quetiapine Fumarate | 448 | $6,476 |
| Fluphenazine Hcl | 37 | $5,014 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $21,772 | $381,792143 claims |
| Alkermes, Inc.Aristada, Lybalvi | $64,817 | $143,16649 claims |
| Sunovion Pharmaceuticals Inc.Latuda | $1,069 | $6,65713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 209 psychiatry providers in Rhode Island.
Other psychiatry in Warwick
- Warren OngWarwick$807K
- Terrie MailhotWarwick$26K
- Ethan KischWarwick$24K
- James GalloWarwick$4K
- David KroesslerWarwick$3K
- Charles DenbyWarwick$2K
- Sandhya PatelWarwick$2K
- Alexander ScagnelliWarwick$983
- Richard WhalenWarwick$661
- Rafael TorresWarwick$476
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.